The Louisiana’s Attorney General sues a pharmaceutical company for violating antitrust rules by filing baseless citizen petitions to the US Food and Drug Administration in order to delay the entry of a generic product in the market (GlaxoSmithKline)

Louisiana’s Attorney General sues GlaxoSmithKline over delay of generic nasal spray* In December 2014 Louisiana’s attorney general (AG) filed a complaint against GlaxoSmithKline (GSK) alleging that GSK engaged in an anticompetitive scheme to delay the entry of a generic version of its Flonase nasal spray. This is the third time since 2011 that AG James D. “Buddy” Caldwell has filed suit against GSK. The lawsuit alleges that the state’s antitrust and unfair

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • DLA Piper Weiss-Tessbach (Vienna)

Quotation

Nicole Daniel, The Louisiana’s Attorney General sues a pharmaceutical company for violating antitrust rules by filing baseless citizen petitions to the US Food and Drug Administration in order to delay the entry of a generic product in the market (GlaxoSmithKline), 29 December 2014, e-Competitions Bulletin December 2014, Art. N° 72177

Visites 244

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues